HERON THERAPEUTICS, INC. /DE/ (HRTX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
HRTX currently has 170M outstanding shares. with limited dilution risk as only 16.5M additional shares (9.7%) are authorized for issuance. The company has significantly diluted shareholders by 172.58% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 04, 2025 |
10-Q filing | 170.3M shares outstanding |
170M | 17M |
| Sep 09, 2025 |
S-3 filing: Heron Therapeutics files an S-3 shelf registration to offer an aggregate of $125,000,000 of common stock, preferred stock, debt securities, warrants, rights or units. |
150M | 33M |
| Sep 09, 2025 |
S-3 filing: This prospectus relates to the potential resale or other disposition by the selling stockholders of an aggregate of 37,911,081 shares of common stock of Heron Therapeutics, Inc. |
400M | 0 |
| Aug 08, 2025 |
8-K filing: Heron Therapeutics, Inc. entered into a securities purchase agreement for the private sale of 13,225,227 unregistered shares of common stock and 524,141 unregistered shares of Series A Convertible Preferred Stock at $1.50 per share for an aggregate investment amount of approximately $27.7 million, with the preferred stock automatically converting into 5,241,410 shares of common stock upon stockholder approval. ($20.62M proceeds) |
150M | 0 |
| Aug 08, 2025 |
10-Q filing | 154.0M shares outstanding |
150M | 0 |
| May 06, 2025 |
10-Q filing | 153.5M shares outstanding |
150M | 0 |
| Feb 27, 2025 |
10-K filing | 152.4M shares outstanding |
150M | 0 |
| Nov 12, 2024 |
10-Q filing | 152.8M shares outstanding |
150M | 0 |
| Aug 06, 2024 |
10-Q filing | 152.3M shares outstanding |
150M | 0 |
| May 07, 2024 |
10-Q filing | 151.2M shares outstanding |
150M | 0 |
| Mar 12, 2024 |
10-K filing | 138.1M shares outstanding |
140M | 11M |
| Nov 14, 2023 |
10-Q filing | 145.0M shares outstanding |
140M | 4M |
| Aug 23, 2023 |
S-3 filing: Heron Therapeutics, Inc. is offering 21,897,808 shares of common stock on a resale basis by selling stockholders. |
140M | 8.2M |
| Aug 14, 2023 |
10-Q filing | 140.8M shares outstanding |
140M | 0 |
| May 11, 2023 |
10-Q filing | 119.2M shares outstanding |
120M | 7.8M |
| Mar 29, 2023 |
10-K filing | 119.3M shares outstanding |
120M | 7.8M |
| Nov 08, 2022 |
10-Q filing | 111.7M shares outstanding |
110M | 15M |
| Oct 07, 2022 |
S-3 filing: This S-3 filing registers the resale of 24,677,419 shares of common stock by selling stockholders, including shares issuable upon exercise of pre-funded warrants. The company will not receive proceeds from the sales, except for the nominal exercise price of the warrants. |
120M | 8.3M |
| Aug 09, 2022 |
10-Q filing | 102.4M shares outstanding |
100M | 0 |
| May 09, 2022 |
10-Q filing | 102.5M shares outstanding |
100M | 0 |
| Feb 28, 2022 |
10-K filing | 102.1M shares outstanding |
100M | 0 |
| Nov 03, 2021 |
10-Q filing | 101.9M shares outstanding |
100M | 0 |
| Aug 09, 2021 |
10-Q filing | 101.9M shares outstanding |
100M | 0 |
| May 10, 2021 |
10-Q filing | 101.8M shares outstanding |
100M | 0 |
| Feb 24, 2021 |
10-K filing | 91.4M shares outstanding |
91M | 0 |
| Nov 05, 2020 |
10-Q filing | 90.9M shares outstanding |
91M | 0 |
| Aug 05, 2020 |
10-Q filing | 90.9M shares outstanding |
91M | 0 |
| May 06, 2020 |
10-Q filing | 90.6M shares outstanding |
91M | 0 |
| Mar 02, 2020 |
10-K filing | 90.4M shares outstanding |
90M | 0 |